These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 32793213)

  • 1. Specificity of the T Cell Response to Protein Biopharmaceuticals.
    Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
    Front Immunol; 2020; 11():1550. PubMed ID: 32793213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applying MAPPs Assays to Assess Drug Immunogenicity.
    Karle AC
    Front Immunol; 2020; 11():698. PubMed ID: 32373128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.
    Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS
    Front Immunol; 2020; 11():1301. PubMed ID: 32695107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies.
    Mattei AE; Gutierrez AH; Seshadri S; Tivin J; Ardito M; Rosenberg AS; Martin WD; De Groot AS
    MAbs; 2024; 16(1):2333729. PubMed ID: 38536724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.
    Coutinho A; Caramalho I; Seixas E; Demengeot J
    Curr Top Microbiol Immunol; 2005; 293():43-71. PubMed ID: 15981475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay.
    Schultz HS; Reedtz-Runge SL; Bäckström BT; Lamberth K; Pedersen CR; Kvarnhammar AM;
    PLoS One; 2017; 12(5):e0178544. PubMed ID: 28562666
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Ito S; Ikuno T; Mishima M; Yano M; Hara T; Kuramochi T; Sampei Z; Wakabayashi T; Tabo M; Chiba S; Kubo C
    J Immunotoxicol; 2019 Dec; 16(1):125-132. PubMed ID: 31179789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of protein particle characterization and understanding its potential to diminish the immunogenicity of biopharmaceuticals: a shared perspective.
    Bee JS; Goletz TJ; Ragheb JA
    J Pharm Sci; 2012 Oct; 101(10):3580-5. PubMed ID: 22736570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.
    Xue L; Hickling T; Song R; Nowak J; Rup B
    Clin Exp Immunol; 2016 Jan; 183(1):102-13. PubMed ID: 26400440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.
    De Groot AS; Terry F; Cousens L; Martin W
    Expert Rev Clin Pharmacol; 2013 Nov; 6(6):651-62. PubMed ID: 24164613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells.
    Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S
    MAbs; 2021; 13(1):1898831. PubMed ID: 33729092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays.
    Walsh RE; Nix A; Ackaert C; Mazy A; Schockaert J; Pattyn S; Malherbe L
    Front Immunol; 2024; 15():1406040. PubMed ID: 38863708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.
    Nabhan M; Pallardy M; Turbica I
    Front Immunol; 2020; 11():725. PubMed ID: 32431697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.
    Karle A; Spindeldreher S; Kolbinger F
    MAbs; 2016; 8(3):536-50. PubMed ID: 26817498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthy Donors Exhibit a CD4 T Cell Repertoire Specific to the Immunogenic Human Hormone H2-Relaxin before Injection.
    Azam A; Gallais Y; Mallart S; Illiano S; Duclos O; Prades C; Maillère B
    J Immunol; 2019 Jun; 202(12):3507-3513. PubMed ID: 31101669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.